Management and Treatment of Chronic HBV and HCV Co-Infection and the Impact of Anti-Viral Therapy

Management and Treatment of Chronic HBV and HCV Co-Infection and the Impact of Anti-Viral Therapy Curr Hepatology Rep (2017) 16:169–177 DOI 10.1007/s11901-017-0352-z HEPATITIS B (J LIM, SECTION EDITOR) Management and Treatment of Chronic HBV and HCV Co-Infection and the Impact of Anti-Viral Therapy 1 2 Mitchell L. Shiffman & Nadege T. Gunn Published online: 19 July 2017 Springer Science+Business Media, LLC 2017 . . Abstract Keywords Hepatitis B virus Hepatitis C virus . . Purpose of Review Recent reports have demonstrated that Co-infection Direct-acting anti-viral agents Peginterferon chronic hepatitis B virus (HBV) can flare or reactivate when alpha Ribavarin chronic hepatitis C virus (HCV) is treated with direct-acting anti-viral agents (DAAs). Understanding HBV and HCV co- infection is therefore important. Epidemiology Recent Findings Although 40–60% of patients with chronic HCV have been previously exposed to HBV; only about 1– Chronic viral hepatitis B (HBV) and C (HCV) collectively 6% has serologic evidence of co-infection. In some patients represent the most common cause of chronic liver disease with co-infection, both HBsurface antigen and HBV DNA worldwide. An estimated 350 million persons have chronic may be suppressed to undetectable levels by HCV. Complete HBV [1]. The areas of the world with the highest prevalence serologic screening for HBV should be performed in all pa- for HBV http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Hepatology Reports Springer Journals

Management and Treatment of Chronic HBV and HCV Co-Infection and the Impact of Anti-Viral Therapy

Loading next page...
 
/lp/springer_journal/management-and-treatment-of-chronic-hbv-and-hcv-co-infection-and-the-Iop4hlUoh6
Publisher
Springer US
Copyright
Copyright © 2017 by Springer Science+Business Media, LLC
Subject
Medicine & Public Health; Hepatology
eISSN
2195-9595
D.O.I.
10.1007/s11901-017-0352-z
Publisher site
See Article on Publisher Site

Abstract

Curr Hepatology Rep (2017) 16:169–177 DOI 10.1007/s11901-017-0352-z HEPATITIS B (J LIM, SECTION EDITOR) Management and Treatment of Chronic HBV and HCV Co-Infection and the Impact of Anti-Viral Therapy 1 2 Mitchell L. Shiffman & Nadege T. Gunn Published online: 19 July 2017 Springer Science+Business Media, LLC 2017 . . Abstract Keywords Hepatitis B virus Hepatitis C virus . . Purpose of Review Recent reports have demonstrated that Co-infection Direct-acting anti-viral agents Peginterferon chronic hepatitis B virus (HBV) can flare or reactivate when alpha Ribavarin chronic hepatitis C virus (HCV) is treated with direct-acting anti-viral agents (DAAs). Understanding HBV and HCV co- infection is therefore important. Epidemiology Recent Findings Although 40–60% of patients with chronic HCV have been previously exposed to HBV; only about 1– Chronic viral hepatitis B (HBV) and C (HCV) collectively 6% has serologic evidence of co-infection. In some patients represent the most common cause of chronic liver disease with co-infection, both HBsurface antigen and HBV DNA worldwide. An estimated 350 million persons have chronic may be suppressed to undetectable levels by HCV. Complete HBV [1]. The areas of the world with the highest prevalence serologic screening for HBV should be performed in all pa- for HBV

Journal

Current Hepatology ReportsSpringer Journals

Published: Jul 19, 2017

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off